

HEPATITIS C VIRUS TREATMENT-RELATED ANEMIA AND ITS ASSOCIATION WITH HIGHER SUSTAINED VIROLOGIC

RESPONSE RATE


López-Sepúlveda, R. García-Collado, C; Pérez-Morales, J; Valencia-Soto, C.; Orantes, J.; Martínez-Casanova, N.

UGC Farmacia Intercentros Interniveles. H. U. Virgen de las Nieves. Granada.

OBJETIVES

Some authors have described that Among Hepatitis C Virus (HCV) genotype 1-infected patients

treated with bitherapy, anemia was associated with higher rates of Sustained Virologic Response (SVR) as well as the use of erythropoiesis-stimulating agents. We investigated the relationships among treatment outcomes, anemia, and their management with Ribavirin dose reduction and/or darbepoetin in patients treated with Boceprevir (BOC) or Telaprevir (TLV) in a tertiary hospital.




records were reviewed	 -basal Hb, -Anemia (Hb<10,5 g/dL), -reduction of ribavirin dose, -use of darbepoetin. 	VS I SVR

RESULTS

36 patients were studied (26 men and 10 women). 23 (63.8%) patients were treated with TLV and 13 (36.2%) with BOC. Data shown in Table. 12 patients (33.3%) used darbepoetin (6 (26.1%) for TLV and 6 (46.1%) for BOC); 8 of these 12 (66.6%) patients showed SVR, 1 relapsed

Variable	TLV	BOC
	(n=23)	(n=13)
SVR	16 (69.5%)	9 (69.2%)
Total Anemia	9 (39.1%)	8 (61.5%)
Anemia in SVR	7 (43,8%)	5 (55.6%)
RBV dose	8 (34.8%)	8 (61.5%)



and 3 abandoned treatment due to adverse events (4)

(66.6%) for TLV and 4 (66.6%) for BOC).

CONCLUSIONS

1. Among our genotype 1-infected patients treated with BOC or TLV anemia was not associated with higher rates of SVR.

2. Patients with darbepoetin did not have higher rates of SVR.

3. Percentages of SVR were similar between TLV and BOC.